Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Nov 19, 2014

Sanofi and Regeneron Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol

- All six trials met primary efficacy endpoint -
Oct 28, 2014

Sanofi: Sanofi Delivers Business EPS Growth of 10.3% at CER
- Photos 1
Oct 20, 2014

Sanofi and Regeneron Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis
Oct 15, 2014

New Survey Finds Differences In Attitudes About Diabetes Based On Age
Sep 17, 2014

Sanofi and MyoKardia Announce Groundbreaking Collaboration to Develop Targeted Therapies for Patients with Genetic Heart Disease

- Up to $200 Million Collaboration to Support Pioneering Science and New Treatments -
- Photos 1
Aug 12, 2014

Sanofi Launches Authorized Generic Version of Eloxatin® (oxaliplatin injection)

Generics Division of Sanofi, Winthrop US, to Market the Drug
- Photos 6
Aug 11, 2014

Sanofi and MannKind Announce Global Licensing Agreement for Afrezza® (insulin human) Rapid-Acting Inhaled Insulin
Aug 7, 2014

Sanofi Licenses Immune Design's GLAAS Platform to Explore Novel Approach to Treat Food Allergy
Jul 31, 2014

Sanofi: Solid Sales and Business EPS Growth at CER
- Photos 1
Jul 9, 2014

Sanofi and Regeneron Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis

- Results from Earlier Clinical Trials Published Today in the New England Journal of Medicine –

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.